Form 4: Alector CEO Arnon Rosenthal Boosts Equity Stake with RSU and Option Grants

Alector, Inc.'s Chief Executive Officer, Arnon Rosenthal, has acquired 137,125 restricted stock units and 45,700 employee stock options, significantly increasing his beneficial ownership in the company.

Summary

• Arnon Rosenthal, Chief Executive Officer and Director of Alector, Inc. (ALEC), acquired 137,125 shares of Common Stock in the form of Restricted Stock Units (RSUs) on July 1, 2025, at a price of $0.00 per share.
• These RSUs are scheduled to vest with one-half (1/2) of the total shares on December 1, 2025, and one-fourth (1/4th) of the total shares vesting quarterly thereafter.
• Rosenthal also acquired 45,700 Employee Stock Options on July 1, 2025, with an exercise price of $1.42 per share and an expiration date of July 1, 2035.
• The employee stock options will vest one-third (1/3rd) of the total shares on November 1, 2025, and one-twelfth (1/12th) of the total shares in equal monthly installments thereafter, with full vesting by July 1, 2026.
• Following these transactions, Rosenthal's direct beneficial ownership of Common Stock is 2,551,782 shares.
• Indirect beneficial ownership of Common Stock totals 3,930,375 shares, held across The Rosenthal Family Revocable Trust (1,972,875 shares), the Adi Rosenthal 2007 Trust (652,500 shares), the Noam Rosenthal 2007 Trust (652,500 shares), and the Shani Rosenthal 2007 Trust (652,500 shares).
• Total beneficial ownership of Common Stock is 6,482,157 shares, and 45,700 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: The acquisition of significant equity and options by the CEO generally indicates confidence in the company's future and aligns management's interests with shareholders. While it's compensation rather than a cash purchase, it's a positive signal for long-term commitment.

Positives

• Chief Executive Officer Arnon Rosenthal is increasing his equity stake in Alector, Inc., signaling confidence in the company's future prospects.
• The acquisition of 137,125 Restricted Stock Units (RSUs) at a $0.00 price represents a significant grant of equity compensation, aligning the CEO's interests with long-term shareholder value.
• The acquisition of 45,700 Employee Stock Options provides additional long-term incentive for the CEO, further strengthening the alignment of management's interests with those of shareholders.
• The multi-year vesting schedules for both RSUs and stock options, extending into 2025 and 2026, indicate a commitment to sustained performance and long-term tenure.

Negatives

• The Restricted Stock Units were acquired at a $0.00 price, indicating they are compensation grants rather than a direct cash investment by the CEO.
• The vesting schedules mean the shares are not immediately available for sale, tying the CEO's liquidity to future performance and continued employment.

Risks

• The ultimate value of the acquired Restricted Stock Units and employee stock options is directly dependent on the future performance of Alector, Inc.'s stock price.
• Vesting conditions for both the RSUs and stock options require continued employment and adherence to specific future dates, which could be impacted by unforeseen circumstances.

Future Outlook

The vesting schedules for the acquired Restricted Stock Units and Employee Stock Options extend into 2025 and 2026, indicating a long-term incentive structure for the CEO tied to future company performance and continued tenure.

Industry Context

This Form 4 filing reflects a standard practice of executive compensation in the biotechnology or pharmaceutical industry, where equity grants like RSUs and stock options are common tools to align management incentives with long-term shareholder value creation, particularly in companies like Alector, Inc. (ALEC) which are often in development phases.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Employee Stock Options as a significant component of executive compensation is a common practice across the biotechnology and pharmaceutical sectors, similar to companies such as Biogen Inc. (BIIB) or Regeneron Pharmaceuticals, Inc. (REGN), which frequently utilize such equity grants to retain talent and incentivize long-term performance.
• The vesting schedules, with portions vesting over several quarters or years, are typical for executive equity awards, designed to encourage sustained commitment and performance, aligning with governance best practices seen at peer companies.
• The $0.00 acquisition price for RSUs is standard for such grants, representing compensation rather than a direct purchase, while the exercise price of $1.42 for options would be compared to the market price of ALEC shares on the grant date to assess its 'in-the-money' or 'out-of-the-money' status, a common metric in compensation analysis.

Related Party Transactions

• The indirect beneficial ownership of Common Stock through The Rosenthal Family Revocable Trust Dated November 4, 1994 (restated June 9, 1999), for which Arnon Rosenthal serves as trustee.
• The indirect beneficial ownership of Common Stock through the Adi Rosenthal 2007 Trust dated March 27, 2007, for which Arnon Rosenthal serves as trustee.
• The indirect beneficial ownership of Common Stock through the Noam Rosenthal 2007 Trust dated March 27, 2007, for which Arnon Rosenthal serves as trustee.
• The indirect beneficial ownership of Common Stock through the Shani Rosenthal 2007 Trust dated March 27, 2007, for which Arnon Rosenthal serves as trustee.

Stakeholder Impact

• Shareholders: The acquisition of additional equity and options by the CEO aligns his interests with shareholders, potentially signaling management's confidence in future stock performance and long-term value creation.
• Employees: This transaction is part of executive compensation, which can set a precedent or reflect the company's overall compensation philosophy, potentially influencing employee morale and retention strategies.

Next Steps

• Future vesting events for the Restricted Stock Units on December 1, 2025, and quarterly thereafter.
• Future vesting events for the Employee Stock Options on November 1, 2025, and monthly thereafter, with full vesting by July 1, 2026.
• Potential exercise of employee stock options by July 1, 2035.

Key Dates

Recommendation

Keywords

Alector Inc., ALEC, SEC Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, RSUs, Employee Stock Options, CEO Compensation, Arnon Rosenthal, Equity Grant, Beneficial Ownership, Corporate Governance